Do not treat all CLL patients with fludarabine by Bosanquet, A, Johnson, SA, Richards, S

Prognosis for fludarabine therapy of chronic lymphocytic leukaemia based on ex vivo drug response by DiSC assay. by Bosanquet, A, Johnson, SA, Richards, S

High mortality of DiSC assay-resistant CLL patients treated with fludarabine. by Bosanquet, A, Johnson, SA, Richards, S

Designing enzymes with ROSETTA: Challenges and solutions by Kim, S, Kiss, G, Paton, R, Johnson, SA, Nosrati, G, Houk, K

Evaluating the impact of national education in pediatric palliative care: the Quality of Care Collaborative Australia by Slater PJ, Herbert AR, Baggio SJ, Donovan LA, McLarty AM, Duffield JA, Pedersen LC, Duc JK, Delaney AM, Johnson SA, Heywood MG, Burr CA

Get full text

The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants by Liu, C, Zhou, D, Nutalai, R, Duyvesteyn, HME, Tuekprakhon, A, Ginn, HM, Dejnirattisai, W, Supasa, P, Mentzer, AJ, Wang, B, Case, JB, Zhao, Y, Skelly, DT, Chen, RE, Johnson, SA, Ritter, TG, Mason, C, Malik, T, Temperton, N, Paterson, NG, Williams, MA, Hall, DR, Clare, DK, Howe, A, Goulder, PJR, Fry, EE, Diamond, MS, Mongkolsapaya, J, Ren, J, Stuart, DI, Screaton, GR

Potent cross-reactive antibodies following Omicron breakthrough in vaccinees by Nutalai, R, Zhou, D, Tuekprakhon, A, Ginn, HM, Supasa, P, Liu, C, Huo, J, Mentzer, AJ, Duyvesteyn, HME, Dijokaite-Guraliuc, A, Skelly, D, Ritter, TG, Amini, A, Bibi, S, Adele, S, Johnson, SA, Constantinides, B, Webster, H, Temperton, N, Klenerman, P, Barnes, E, Dunachie, SJ, Crook, D, Pollard, AJ, Lambe, T, Goulder, P, Paterson, NG, Williams, MA, Hall, DR, Mongkolsapaya, J, Fry, EE, Dejnirattisai, W, Ren, J, Stuart, DI, Screaton, GR

Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum by Tuekprakhon, A, Nutalai, R, Dijokaite-Guraliuc, A, Zhou, D, Ginn, HM, Selvaraj, M, Liu, C, Mentzer, AJ, Supasa, P, Duyvesteyn, HME, Das, R, Skelly, D, Ritter, TG, Amini, A, Bibi, S, Adele, S, Johnson, SA, Constantinides, B, Webster, H, Temperton, N, Klenerman, P, Barnes, E, Dunachie, SJ, Crook, D, Pollard, AJ, Lambe, T, Goulder, P, Paterson, NG, Williams, MA, Hall, DR, ISARIC4C Consortium, Fry, EE, Huo, J, Mongkolsapaya, J, Ren, J, Stuart, DI, Screaton, GR

A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75 by Huo, J, Dijokaite-Guraliuc, A, Liu, C, Zhou, D, Ginn, HM, Das, R, Supasa, P, Selvaraj, M, Nutalai, R, Tuekprakhon, A, Duyvesteyn, HME, Mentzer, AJ, Skelly, D, Ritter, TG, Amini, A, Bibi, S, Adele, S, Johnson, SA, Paterson, NG, Williams, MA, Hall, DR, Plowright, M, Newman, TAH, Hornsby, H, de Silva, TI, Temperton, N, Klenerman, P, Barnes, E, Dunachie, SJ, Pollard, AJ, Lambe, T, Goulder, P, OPTIC consortium, ISARIC4C consortium, Fry, EE, Mongkolsapaya, J, Ren, J, Stuart, DI, Screaton, GR

Divergent trajectories of antiviral memory after SARS-CoV-2 infection by Tomic, A, Skelly, DT, Ogbe, A, O'Connor, D, Pace, M, Adland, E, Alexander, F, Ali, M, Allott, K, Azim Ansari, M, Belij-Rammerstorfer, S, Bibi, S, Blackwell, L, Brown, A, Brown, H, Cavell, B, Clutterbuck, EA, de Silva, T, Eyre, D, Lumley, S, Flaxman, A, Grist, J, Hackstein, C-P, Halkerston, R, Harding, AC, Hill, J, James, T, Jay, C, Johnson, SA, Kronsteiner, B, Lie, Y, Linder, A, Longet, S, Marinou, S, Matthews, PC, Mellors, J, Petropoulos, C, Rongkard, P, Sedik, C, Silva-Reyes, L, Smith, H, Stockdale, L, Taylor, S, Thomas, S, Tipoe, T, Turtle, L, Vieira, VA, Wrin, T, Pollard, AJ, Lambe, T, Frater, J, Mentzer, AJ, James, WS, Barnes, E, Dunachie, SJ

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses by Dejnirattisai, W, Huo, J, Zhou, D, Zahradník, J, Supasa, P, Liu, C, Duyvesteyn, HME, Ginn, HM, Mentzer, AJ, Tuekprakhon, A, Nutalai, R, Wang, B, Dijokaite, A, Khan, S, Avinoam, O, Bahar, M, Skelly, D, Adele, S, Johnson, SA, Amini, A, Ritter, TG, Mason, C, Dold, C, Pan, D, Assadi, S, Bellass, A, Omo-Dare, N, Koeckerling, D, Flaxman, A, Jenkin, D, Aley, PK, Voysey, M, Costa Clemens, SA, Naveca, FG, Nascimento, V, Nascimento, F, Fernandes da Costa, C, Resende, PC, Pauvolid-Correa, A, Siqueira, MM, Baillie, V, Serafin, N, Kwatra, G, Da Silva, K, Madhi, SA, Nunes, MC, Malik, T, Openshaw, PJM, Baillie, JK, Semple, MG, Dunachie, SJ, Lambe, T, Screaton, GR, Pollard, AJ

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum by Liu, C, Ginn, HM, Dejnirattisai, W, Supasa, P, Wang, B, Tuekprakhon, A, Nutalai, R, Zhou, D, Mentzer, AJ, Zhao, Y, Duyvesteyn, HME, López-Camacho, C, Slon-Campos, J, Walter, TS, Skelly, D, Johnson, SA, Ritter, TG, Mason, C, Costa Clemens, SA, Gomes Naveca, F, Nascimento, V, Nascimento, F, Fernandes da Costa, C, Resende, PC, Pauvolid-Correa, A, Siqueira, MM, Dold, C, Temperton, N, Dong, T, Pollard, AJ, Knight, JC, Crook, D, Lambe, T, Clutterbuck, E, Bibi, S, Flaxman, A, Bittaye, M, Belij-Rammerstorfer, S, Gilbert, SC, Malik, T, Carroll, MW, Klenerman, P, Barnes, E, Dunachie, SJ, Baillie, V, Serafin, N, Ditse, Z, Da Silva, K, Paterson, NG, Williams, MA, Goulder, P, Fry, EE, Ren, J, Stuart, DI, Screaton, GR